Vicasinabin

Vicasinabin

Identifiers
IUPAC name (3S)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol
CAS Number	1433361-02-4
PubChem CID	86296048
Chemical and physical data
Formula	C15H22N10O
Molar mass	358.410 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)(C)C1=NC2=C(C(=N1)N3CC[C@@H](C3)O)N=NN2CC4=NN=NN4C
InChI InChI=1S/C15H22N10O/c1-15(2,3)14-16-12(24-6-5-9(26)7-24)11-13(17-14)25(21-19-11)8-10-18-20-22-23(10)4/h9,26H,5-8H2,1-4H3/t9-/m0/s1 Key:MAYZWDRUFKUGGP-VIFPVBQESA-N

Vicasinabin (RG7774) is a potent cannabinoid agonist which is highly selective for the CB₂ receptor subtype. It was developed by Roche as a potential agent for the treatment of diabetic retinopathy. It reached Phase II human clinical trials but was discontinued for lack of efficacy, although it continues to be used for scientific research. ^{[1] [2]}

References

1. Grether U, Foxton RH, Gruener S, Korn C, Kimbara A, Osterwald A, et al. (2024). "RG7774 (Vicasinabin), an orally bioavailable cannabinoid receptor 2 (CB2R) agonist, decreases retinal vascular permeability, leukocyte adhesion, and ocular inflammation in animal models". Frontiers in Pharmacology. 15: 1426446. doi: 10.3389/fphar.2024.1426446 . PMC   11272598 . PMID   39070793.
2. Armendariz BG, Luhman UF, Berger B, Hernandez-Sanchez J, Bogman K, Mitrousis N, et al. (2025). "CANBERRA: A Phase II Randomized Clinical Trial to Test the Therapeutic Potential of Oral Vicasinabin in Diabetic Retinopathy". Ophthalmology Science. 5 (2): 100650. doi:10.1016/j.xops.2024.100650. PMC   11719906 . PMID   39802207.